ADCs

Re-Engineering ADCs for Autoimmune and Inflammatory Disease

David Alvaro, Ph.D.

Pharma's Almanac

Nobel Prize

Peacekeepers of Immunity: The Nobel-Winning Discovery That Redefined Immunity

David Alvaro, Ph.D.

Pharma's Almanac

Ovarian Cancer

Ovarian Cancer at an Inflection Point: Quantifying the Burden, Closing Gaps, and Accelerating Next-Generation Therapies

David Alvaro, Ph.D.

Pharma's Almanac

Antibodies

Co-Founders of Biotech Avidicure Talk New Antibody Modality, Starting from Scratch, and $50M Launch

Robert Friesen, Ph.D.; Govert Schouten; Arthur Lahr

Avidicure

In Situ Engineering

Engineering from Within via In Situ Programming and Regeneration

David Alvaro, Ph.D.

Pharma's Almanac

Oncology

From Chemo to Advanced Therapies: New Frontiers in Oncology

Serene Lee

Nice Insight

LOGIC GATES

Boolean Biology: The Future of Logic-Gated Cell and Gene Therapies

David Alvaro, Ph.D.

Pharma's Almanac

Immuno-oncology

Immuno-Oncology at the Forefront of Cancer Medicine

David Alvaro, Ph.D.

Pharma's Almanac

Bioassays

Developing a Toolbox of Functional Bioassays for Optimizing ADCC

Anke Hartung, Ph.D.,

Tanvex CDMO

CDMO - Small Biotech

Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility

Julie Trulson, Ph.D.

Tech Transfer

Transparent Communication Supports Tech Transfers Of Cis-targeted Immunotherapies

Julie Trulson, Ph.D.

Vaccines

Delivering a Next-Generation COVID-19 Vaccine for Immunocompromised Patients and Novel Cancer Vaccines

David Dodd; Mark Newman, Ph.D.

GeoVax Inc.

Cell Therapy

Engineering Immune Cells to Realize the Promise of Cancer Cell Therapies

Beau Webber, Ph.D.

Luminary Therapeutics

Artificial Intelligence

Using Artificial Intelligence to Get the Right Drug to the Right Patient at the Right Time

Stefan Weiss, M.D.

Anti-Idiotype Antibodies

Rapid Supply of Anti-Idiotype Antibodies Facilitates Preclinical and Clinical Antibody-Based Drug Development

Na Li, Ph.D.

Sino Biological

Collaboration

AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets

Anima Biotech Inc.

Immuno-Oncology

Targeted Immune System Activation: A Paradigm Shift in Immuno-oncology

Dan Passeri, M.Sc., J.D.

Cue Biopharma

CAR-T

Enabling Greater Patient Access to CAR-T Cell Therapies with Off-the-Shelf Delivery Solutions

Ryan Larson, Ph.D.

Umoja Biopharma